Since 1989 an increasing number of patients has been described who all have a low concentration of coenzyme Q10 in skeletal muscle and/or fibroblasts but display diverse pathological phenotypes of mainly neuromuscular and nephrotic diseases. The biosynthesis pathway of coenzyme Q10 is very complex and partially unknown. The objective of this publication is to provide an update for basic and clinical scientists on the current knowledge of this pathway and its defects including the genes involved and the role of coenzyme Q10 in the mitochondrial respiratory chain. Different approaches to studying the syndrome are discussed such as biochemical and genetic diagnosis, clinical presentations and pathogenesis. Major advances in the understanding of the development of the diseases caused by coenzyme Q10 deficiency and their variability come from the study of animal models; they are covered in the chapters on invertebrate and mice models. Finally, currently available therapies as well as new therapeutic approaches are presented.

Reflecting the current view of coenzyme Q10 biosynthesis and its major role in the respiratory chain, this publication is of interest to biochemists and neurologists working on mitochondria and bioenergetics, particularly those involved in the diagnosis and treatment of mitochondrial diseases.
the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy are available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges/ Length of Paper
There are no page charges for papers of 3 or fewer printed pages (including tables, figures, references and acknowledgements). Each additional complete or partial page is charged to the author at CHF 325.00.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerable higher prices.

A Uniform Clinical Trial Registration Policy for Journals of Kidney Diseases, Dialysis and Transplantation
Clinical trials provide important information that can profoundly influence the direction of medical research and clinical care. It is crucial that this process is not unduly influenced by selective publication of clinical trial results. Information regarding all clinical trials should therefore be made available to the general public.

In common with other nephrology journals, Nephron requires that from 2006 all submitted manuscripts concerning clinical trials must be registered in a public trials registry. The full text of a recent statement published by the editors of Kidney International; The Journal of the American Society of Nephrology; Nephrology, Dialysis, Transplantation; The American Journal of Transplantation; The American Journal of Kidney Diseases, and Transplantation is reproduced below. The policy described in this text has now been formally adopted by Nephron. Medical research can be seriously compromised by the selective publication of clinical trial results. Therefore, it is imperative that information regarding clinical trials should be available to the general public.

We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. Since 1 April 2006, Nephron no longer accepts manuscripts concerning non-registered trials.

We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase 1 trials) are exempt.

We do not advocate any one particular registry, but registration must be with a registry that meets the following minimum criteria:

- Accessible to the public at no charge.
- Searchable by standard, electronic (internet-based) methods.
- Open to all prospective registrants free of charge or at minimal cost.
- Validates registered information.
- Identifies trials with a unique number.
- Includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).

Registries that currently meet these criteria include:

- The registry sponsored by the US National Library of Medicine www.clinicaltrials.gov
- The International Standard Randomised Controlled Trial Number registry www.isrctn.com
- The Cochrane Renal Group registry www.cochrane-renal.org
- The National (UK) Research Register www.update-software.com/national/
- European Clinical Trials Database https://www.clinicaltrialsregister.eu

The course will be organized in three parts:
- Native Kidney Diseases
- Transplant Kidney Diseases
- Molecular Nephropathology

www.issrp.com

International Summer School of Renal Pathology • 2015
Bari, July 20–31, 2015

We are pleased to announce the fourth CME accredited International Summer School of Renal Pathology to be held at the University of Bari, Italy, from July 20th to July 31st, 2015. The course is endorsed by the RPS as well as ISN, ERA-EDTA and the Italian Society of Nephrology (SIN). Fellowships are available to cover some of the costs of the course.

The course will include:
- Formal lectures (29 hours)
- Independent review of 200 cases (35 hours)
- Small group case study with instructor (group = 12 students; 9 hours/group)
- Practical exercise with Instructor (EM&IF interpretation, reporting renal biopsies, digital pathology, 4 hours)
- Small group electron microscopy room (group = 3 students; 12 hours total)
- Technical aspects: laboratories for small groups (12 hours total)
- Clinical-pathologic conferences (4 hours)

Course Directors
Dr. Laura Barisoni, MD
University of Miami, FL, USA
lbarisoni@med.miami.edu

Dr. Loreto Gesualdo, MD
University of Bari, Italy
lorente.gesualdo@uniba.it

Dr. Surya Seshan, MD
Cornell University, NY, USA
svs2002@med.cornell.edu

Faculty
International faculty from RPS

The Guidelines for Authors are available at: www.karger.com/nef_Guidelines
155 Effect of Neutral pH and Low-Glucose Degradation Product-Containing Peritoneal Dialysis Solution on Residual Renal Function in Peritoneal Dialysis Patients: A Meta-Analysis
Wang, J. (Shanghai/Aachen); Zhu, N. (Shanghai/Berlin); Yuan, W. (Shanghai)

164 Critically Ill Patients Requiring Acute Renal Replacement Therapy Are at an Increased Risk of Long-Term Renal Dysfunction, but Rarely Receive Specialist Nephrology Follow-Up

171 Elevated Serum Free Pregnancy-Associated Plasma Protein-A Independently Predicts Mortality in Haemodialysis Patients but Is Not Associated with Recurrent Haemodialysis-Induced Ischaemic Myocardial Injury
Jeffries, H.J. (Derby); Tertti, R.; Wittfoth, S. (Turku); Burton, J.O. (Derby); Metsärinne, K.; Pettersson, K. (Turku); McIntyre, C.W. (Derby/Nottingham)

179 Improved Survival of Incident Patients with High-Volume Haemodiafiltration: A Propensity-Matched Cohort Study with Inverse Probability of Censoring Weighting
Canaud, B.; Bayh, I.; Marcelli, D. (Bad Homburg); Ponce, P. (Lisbon); Merello, J.I. (Madrid); Gurevich, K. (Saint Petersburg); Ladanyi, E. (Miskolc); Ok, E. (Izmir); Imamovic, G. (Zvornik); Grassmann, A.; Scatizzi, L. (Bad Homburg); Gatti, E. (Bad Homburg/Krems)

189 Effect of Ultrafiltration versus Intravenous Furosemide for Decompensated Heart Failure in Cardiorenal Syndrome: A Systematic Review with Meta-Analysis of Randomized Controlled Trials

197 Vitamin K Antagonists Predispose to Calciphylaxis in Patients with End-Stage Renal Disease

202 Hepatitis B and C Virus Infection in the Hemodialysis Population from Three Romanian Regions
Schiller, A.; Timar, R. (Timisoara); Siriopol, D. (Iasi); Timar, B.; Bob, F.; Schiller, O. (Timisoara); Drug, V. (Iasi); Mihaescu, A. (Timisoara); Covic, A. (Iasi)
209 Establishing a Supportive Care Register Improves End-of-Life Care for Patients with Advanced Chronic Kidney Disease
Harrison, J.K.; Clipsham, L.E.; Cooke, C.M.; Warwick, G.; Burton, J.O. (Leicester)

214 Hemodialysis in Patients Over 80 Years

Clinical Practice: Second Opinion

219 Is ‘Bad Luck’ an Important Determinant of Cancer Incidence and Does This Concept Apply to Kidney Tumors?
Garattini, E.; Tavani, A. (Milano)

Experimental Nephrology and Genetics

Experimental Nephrology and Genetics: Original Paper

223 The Serine Protease Inhibitor Camostat Mesilate Attenuates the Progression of Chronic Kidney Disease through its Antioxidant Effects
Ueda, M. (Kumamoto); Uchimura, K. (Yamanashi); Narita, Y.; Miyasato, Y.; Mizumoto, T.; Morinaga, J.; Hayata, M.; Kakizoe, Y.; Adachi, M.; Miyoshi, T.; Shiraishi, N.; Kadowaki, D. (Kumamoto); Sakai, Y. (Osaka); Mukoyama, M. (Kumamoto); Kitamura, K. (Yamanashi)
JVA, a leading voice in vascular access research and techniques

The Journal of Vascular Access is issued six times per year; it considers the publication of original manuscripts dealing with clinical and laboratory investigations in the fast growing field of vascular access. In addition reviews, case reports and clinical trials are welcome, as well as papers dedicated to more practical aspects covering new devices and techniques. All contributions, coming from all over the world, undergo the peer-review process.

JVA is divided into independent sections, each led by Editors of the highest scientific level:

- Dialysis  •  Oncology  •  Interventional radiology  •  Nutrition  •  Nursing  •  Intensive care

SUBSCRIBE NOW!

To subscribe online go to: www.vascular-access.info/Product/Subscriptions
Or email this form to subscriptions@wichtig.com

Please highlight option required below:

<table>
<thead>
<tr>
<th></th>
<th>Valid until</th>
<th>Type</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual subscription – Europe</td>
<td>31/12/2015</td>
<td>Print+online</td>
<td>285,00 €</td>
</tr>
<tr>
<td>Individual subscription – Online only</td>
<td>31/12/2015</td>
<td>Online only</td>
<td>191,00 €</td>
</tr>
<tr>
<td>Individual subscription – Rest of the</td>
<td>31/12/2015</td>
<td>Print+online</td>
<td>329,00 €</td>
</tr>
<tr>
<td>world</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Institutional subscription – Europe</td>
<td>31/12/2015</td>
<td>Print+online</td>
<td>506,00 €</td>
</tr>
<tr>
<td>Institutional subscription – Online only</td>
<td>31/12/2015</td>
<td>Online only</td>
<td>383,00 €</td>
</tr>
<tr>
<td>Institutional subscription – Rest of the world</td>
<td>31/12/2015</td>
<td>Print+online</td>
<td>550,00 €</td>
</tr>
</tbody>
</table>

SUBSCRIBER’S DETAILS

Name
Job title
Postal address
Invoicing address
VAT Number
E-mail

PAYMENT OPTIONS

☐ CREDIT CARD
Payment card ☐ Amex ☐ Master Card ☐ VISA
Cardholder name
Card No._________________________________________________________
CVV/CVC_________________________ Expiry Date_____________________

☐ BANK TRANSFER
Banca Intesa SANPAOLO spa Milano
Swift: BCITITMMXXX - IBAN: IT51U030690463000009950033
Signature

For full terms and conditions please go online to: www.vascular-access.info